February 25, 2020 / 8:57 AM / a month ago

BRIEF-IMV Announces Data From Phase 2 Study Of DPX-Survivac In Patients With Advanced Recurrent Ovarian Cancer

Feb 25 (Reuters) - IMV Inc:

* ANNOUNCES BREAKTHROUGH DATA FROM DECIDE1, ITS ONGOING PHASE 2 STUDY OF DPX-SURVIVAC IN PATIENTS WITH ADVANCED RECURRENT OVARIAN CANCER

* TREATMENT WELL-TOLERATED WITH LIMITED SIDE EFFECTS OBSERVED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below